DOCETAXEL INJECTION 10 MG — DIN 02439336
DOCETAXEL : 10 MG · SANDOZ CANADA INCORPORATED · Injection · wholesale supply in Canada
Health Canada status: MARKETED
What is DOCETAXEL INJECTION?
DOCETAXEL INJECTION 10 MG contains DOCETAXEL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02439336, held by SANDOZ CANADA INCORPORATED, supplied as Injection for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 02-Jun-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOCETAXEL INJECTION used for?
Breast Cancer: Docetaxel Injection (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer. Docetaxel Injection, in combination with doxorubicin as first line therapy, should be reserved for patients with potentially life-threatening disease (such as visceral or lung metastatic disease). Docetaxel Injection in combination with capecitabine tablets is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Non-Small Cell Lung Cancer: Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. Ovarian Cancer: Docetaxel Injection is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. Prostate Cancer: Docetaxel Injection in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. Squamous Cell Carcinoma of the Head and Neck: Docetaxel Injection is indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Docetaxel cost around the world?
Docetaxel is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 20 | 37 | SAR███.██ |
| South Africa | single exit price | 29 | 29 | ZAR███.██ |
| Greece | producer price (ex-factory) | 18 | 18 | EUR███.██ |
| Italy | ex-factory (classe H) | 12 | 15 | EUR███.██ |
| Morocco | PPV (public price) | 9 | 13 | MAD███.██ |
| Romania | max producer price | 8 | 12 | RON███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 4 | 11 | BRL███.██ |
| Slovakia | categorised final price | 5 | 6 | EUR███.██ |
| Hungary | producer price (ex-factory) | 5 | 5 | HUF███.██ |
| Iceland | max wholesale | 5 | 5 | ISK███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
162 pack listings across 124 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Docetaxel pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Docetaxel in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Docetaxel, across 15 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BIOLYSE PHARMA CORPORATION | 1 | 1 | DOCETAXEL INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | DOCETAXEL INJECTION USP | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | DOCETAXEL INJECTION | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 3 | 0 | TARO-DOCETAXEL | No marketed DIN |
| ACTAVIS PHARMA COMPANY | 2 | 0 | ACT DOCETAXEL 40 MG/ML | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-DOCETAXEL | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 2 | 0 | TAXOTERE | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | DOCETAXEL INJECTION | No marketed DIN |
| ACCORD HEALTHCARE INC | 1 | 0 | DOCETAXEL INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | Injection |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Docetaxel Injection is available in vials containing 160 mg (16 mL) docetaxel (anhydrous). 16 mL vials are provided in 1 vial per box. |
| Storage | Store the unopened vials between 2°C – 25°C. Retain in the original package to protect from light. Freezing does not adversely affect the product. Docetaxel Injection infusion solutions, if stored between 2°C and 25°C are stable for 4 hours. Fully prepared Docetaxel Injection infusion solution (in either 0.9% sodium chloride solution or 5% dextrose solution) should be used within 4 hours (including the 1 hour IV administration). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Docetaxel |
|---|---|
| ATC code | L01CD02 |
| AHFS class | 86:12.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02439336 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2439336 |
| Brand name | DOCETAXEL INJECTION |
| Generic / active ingredient | DOCETAXEL : 10 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | L01CD02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01CD |
| Current status | MARKETED |
| Status date | 02-Jun-2016 |
| Original market date | 2023-03-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Docetaxel Injection must be administered intravenously. Due to the osmolality of Docetaxel Injection, it is extremely important that the intravenous needle or catheter be properly positioned before any Docetaxel Injection is injected. Leakage into surrounding tissue during intravenous administration of Docetaxel Injection may cause considerable irritation, local tissue necrosis and/or thrombophlebitis. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should be introduced into another vein. Premedication Regimen (see below for prostate cancer): In order to reduce the incidence and severity of fluid retention, all patients should be pretreated with oral corticosteroids. The recommended premedication should consist only of oral corticosteroids, such as dexamethasone 16 mg per day (e.g. 8 mg BID), for 3 days starting one day prior to each Docetaxel Injection administration. Antihistamines have not been shown to be useful in controlling fluid retention. Premedication Regimen for Prostate Cancer: For prostate cancer, given the concurrent use of prednisone or prednisolone, the recommended premedication regimen is oral dexamethasone 8 mg at 12 hours, 3 hours and 1 hour before the Docetaxel Injection infusion. Prophylactic Use of Antibiotics: In order to reduce the incidence of febrile neutropenia and infections, the prophylactic use of antibiotics is recommended to patients treated for head and neck cancer. The treatment should consist of oral fluoroquinolone antibiotics, or equivalent oral or intravenous antibiotics, for 10 days starting on day 5 of each cycle of Docetaxel Injection administration. Prophylactic Use of G-CSF: Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities. See 4.2 Recommended Dose and Dosage Adjustment. In addition to G-CSF, the prophylactic use of antibiotics may provide additional benefit. Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, and Squamous Cell Carcinoma of the Head and Neck: The recommended dosage of Docetaxel Injection is 100 mg/m² administered as a one-hour infusion every 3 weeks. When used in combination, Docetaxel Injection is administered at the recommended dosage of 75 mg/m². Prostate Cancer: The recommended dosage of Docetaxel Injection is 75 mg/m² administered as a one-hour infusion every 3 weeks. Concomitant treatment with prednisone or prednisolone 5 mg orally twice daily is administered continuously. Adjuvant Treatment of Operable Node-Positive Breast Cancer: The Docetaxel Injection dose is 75 mg/m² administered 1-hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² every 3 weeks for 6 courses. Patients with Neutropenia, Cutaneous Reactions or Peripheral Neuropathy: Careful monitoring of neutrophil counts is an essential part of Docetaxel Injection therapy. Docetaxel Injection should not be administered until the neutrophil count is at least 1500 cells/ mm³. Patients who experience febrile neutropenia, severe neutropenia (neutrophil < 500 cells/mm³ for more than one week), severe or cumulative cutaneous reaction, or severe neurosensory signs and/or symptoms during Docetaxel Injection therapy should have the dosage of Docetaxel Injection reduced from 100 mg/m² to 75 mg/m². When Docetaxel Injection is given in combination, the dose of Docetaxel Injection should be reduced from 75 mg/m² to 60 mg/m². If the patient continues to experience these reactions at 60 mg/m², the treatment should be discontinued. Alternatively, prophylactic G-CSF may be used in patients with either prior febrile neutropenia or severe infection in order to maintain dose intensity (see 7 WARNINGS AND PRECAUTIONS). Patients who receive adjuvant therapy for breast cancer and who experience febrile neutropenia should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their Docetaxel Injection dose reduced to 60 mg/m². If G-CSF is not used, the Docetaxel Injection dose should be reduced from 75 to 60 mg/m². Patients who experience grade 3 or 4 stomatitis should have their dose decreased from 75 to 60 mg/m². Patients with Hepatic Impairment: Docetaxel Injection should not be used in patients with serum bilirubin > ULN. Also, Docetaxel Injection should not be used in patients who have ALT and/or AST > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN. Concomitant use with a potent CYP3A4 inhibitor: if systemic administration of a potent CYP3A4 inhibitor cannot be avoided, a dose reduction of Docetaxel Injection should be considered and close monitoring for toxicity is recommended (see 7 WARNINGS AND PRECAUTIONS, General and 9 DRUG INTERACTIONS).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Docetaxel Injection is contraindicated in: patients who have a history of hypersensitivity reactions to docetaxel or any of its excipients, or to other drugs formulated with polysorbate 80 or with polyethylene glycol 300; pregnant women; women who are breast-feeding; and patients with severe liver impairment. Docetaxel Injection should not be used in patients with baseline neutrophil counts of < 1500 cells/mm³. Contraindications for other drugs also apply when combined with Docetaxel Injection: Contraindications for capecitabine tablets also apply to the capecitabine plus Docetaxel Injection combination (Please refer to Product Monograph for capecitabine tablets). Contraindications to prednisone also apply to the combination with Docetaxel Injection (Please refer to Product Monograph for prednisone). Contraindications to doxorubicin and cyclophosphamide also apply to their combination with Docetaxel Injection (Please refer to Product Monographs for doxorubicin and cyclophosphamide).
Warnings and precautions
Docetaxel Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic agents. There is a higher risk of developing severe adverse reactions including toxic death and fatal gastrointestinal hemorrhage in patients with hepatic impairment. Docetaxel Injection should not be used in patients with total bilirubin > ULN or AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN. Docetaxel Injection therapy should not be given to patients with neutrophil counts of less than 1500 cells/mm³. Fatal cases of enterocolitis, including ischemic colitis, colitis and neutropenic enterocolitis have been reported. Severe hypersensitivity reactions, with a potential fatal outcome, requiring the immediate discontinuation of Docetaxel Injection may occur. Patients should be closely monitored. Treatment-related second primary malignancies, including acute myeloid leukemia, may occur. No studies have been conducted to assess the carcinogenic potential of docetaxel. Docetaxel Injection contains ethanol at levels that may cause patients to experience intoxication or feel drunk during and after treatment. Patients are advised to avoid driving, operating machinery, or performing other activities that are dangerous for one to two hours after the infusion of Docetaxel Injection. Health care professionals should consider the alcohol content of Docetaxel Injection when prescribing or administering the drug to patients, particularly in those whom alcohol intake should be avoided or minimized and when using it in conjunction with other medications. Some medications, such as pain relievers and sleep aids, may interact with the alcohol in the docetaxel infusion and worsen the intoxicating effects. Each administration of Docetaxel Injection at 100 mg/m² delivers 2.76 g/m² of ethanol. For a patient with a BSA of 1.85 m², this would deliver 5.1 grams of ethanol. Other docetaxel products may have a different amount of alcohol.
Is Docetaxel in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 03 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 15 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOCETAXEL INJECTION | 20 MG | SOLUTION | BIOLYSE PHARMA CORPORATION | MARKETED | 02458020 |
| DOCETAXEL INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02361957 |
| ACT DOCETAXEL 40 MG/ML | 20 MG / 0.5 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02444410 |
| ACT DOCETAXEL 40 MG/ML | 80 MG / 2 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02441845 |
| DOCETAXEL INJECTION | 80 MG / 2.88 ML | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02412233 |
| DOCETAXEL INJECTION | 20 MG | SOLUTION | ACCORD HEALTHCARE INC | DORMANT | 02437031 |
| DOCETAXEL INJECTION | 20 MG / 0.72 ML | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02412225 |
| PMS-DOCETAXEL | 20 MG / 0.5 ML | KIT ; SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | 02436361 |
| PMS-DOCETAXEL | 80 MG / 2 ML | KIT ; SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | 02436388 |
| TARO-DOCETAXEL | 160 MG / 8 ML | SOLUTION | TARO PHARMACEUTICALS INC | CANCELLED PRE MARKET | 02465655 |
2 · Same class — other molecules in ATC L01CD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Paclitaxel | ABRAXANE FOR INJECTABLE SUSPENSION · AJ-PACLITAXEL · APO-PACLITAXEL INJECTABLE · PACLITAXEL · +9 more | 19 | 5 | Yes |
| Cabazitaxel | CABAZITAXEL FOR INJECTION · JEVTANA | 7 | 5 | Yes |
| Docetaxel | ACT DOCETAXEL 40 MG/ML · DOCETAXEL INJECTION · DOCETAXEL INJECTION USP · PMS-DOCETAXEL · +2 more | 15 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01CE | Irinotecan · Topotecan | 32 | 12 |
| L01CA | Vinblastine · Vincristine · Vindesine · Vinorelbine | 22 | 7 |
| L01CB | Etoposide · Teniposide | 14 | 3 |
| L01CX | Trabectedin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOCETAXEL INJECTION called?
Also recorded in Canada as: {1 (4 ML docetaxel 20 MG/ML Injection) / 1 (50 ML albumin human-kjda 250 MG/ML Injection) } Pack (US), {2 (4 ML docetaxel 20 MG/ML Injection) / 1 (50 ML albumin human-kjda 250 MG/ML Injection) } Pack (US), 16 ML docetaxel 10 MG/ML Injection [Docivyx] (US), 2 ML docetaxel 10 MG/ML Injection [Docivyx] (US), 8 ML docetaxel 10 MG/ML Injection [Docivyx] (US), 4 ML docetaxel 20 MG/ML Injection [Beizray] (US), 1 ML docetaxel 20 MG/ML Injection [Beizray] (US), docetaxel 20 MG/ML Injectable Solution (US), docetaxel 10 MG/ML Injectable Solution (US), 1 ML docetaxel 20 MG/ML Injection (US), 4 ML docetaxel 20 MG/ML Injection (US), 2 ML docetaxel 10 MG/ML Injection (US), 8 ML docetaxel 20 MG/ML Injection (US), 16 ML docetaxel 10 MG/ML Injection (US), 8 ML docetaxel 10 MG/ML Injection (US).
The same molecule, Docetaxel, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Docetaxel | Latin | Brazil, Iceland |
| Docetaxel Accord | Latin | Australia, Iceland |
| DOCETAXEL HOSPIRA | Latin | Saudi Arabia |
| Specrodoce | Latin | Saudi Arabia |
| TAXONTAS | Latin | Brazil |
| Docetaxel BOS | Latin | Saudi Arabia |
| Docetere | Latin | Saudi Arabia |
| LEXUS | Latin | Morocco |
| OKA-DOCETAXEL | Latin | Morocco |
| TAXOTERE | Latin | Bahrain |
| TEQUEL | Latin | Brazil |
| Docetaxel Hikma | Latin | Iceland |
| Docetaxel Kabi | Latin | Iceland |
| DOCETAXEL SPC | Latin | Bahrain |
| DOCETAXEL STADA | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.